Merck & Co., Inc. (MRK) stock news
The latest Merck & Co., Inc. news and press releases. 1 news stories in the last 24 hours, 0.8 times its usual daily coverage. MRK stock report · Market news
Latest news
- Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy? Zacks Investment Research, Nov 18, 8:16 PM UTC
MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers. - Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline? Zacks Investment Research, Nov 18, 4:41 PM UTC
MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets. - Merck stops trials of blood cancer drug after risk assessment Reuters, Nov 17, 9:48 PM UTC
Merck stops trials of blood cancer drug after risk assessment - Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead 247 Wallst, Nov 17, 2:30 PM UTC
SCHD anchors countless retirement portfolios, yet its payout barely budged this past year while living costs kept climbing. Four household-name stocks promise faster raises, but each carries a risk that could undo the... - Merck & Co., Inc. (NYSE:MRK) Share Price Breaks Below Fifty Day Moving Average Following Insider Selling Defense World, Nov 17, 6:44 AM UTC
Merck and Co., Inc. (NYSE: MRK - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday following insider selling activity. The stock has a fifty day moving average of $146.... - Is Merck's Stock Still a Good Buy at $150? The Motley Fool, Nov 16, 7:20 PM UTC
Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on Keytruda are expirin... - How Much Does a 56-Year-Old Need Invested to Replace a $145,000 Salary With Dividends? 247 Wallst, Nov 16, 6:39 PM UTC
Replacing a paycheck with dividends sounds simple until you see the price tag at different yields. Then a few overlooked details, from taxes to payroll deductions, quietly shrink the target, and one risky shortcut cou... - Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive 247 Wallst, Nov 16, 4:47 PM UTC
One melanoma headline turned a $63 stock into a market darling, and Moderna's CEO just told Jim Cramer when patients could get the shot. Does the price already bake in the cancer breakthrough, or is the next catalyst ... - Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November Seeking Alpha, Nov 16, 5:47 AM UTC
I expect Nike (NKE) to raise its dividend 1.2–2.4%, as weak sales, flat EPS and a payout ratio around 80% constrain growth. Matthews International (MATW) risks a dividend cut; Hormel (HRL) faces an above-100% payout r... - Merck & Co., Inc. $MRK Stock: Aberdeen Group plc Decreases Stake Defense World, Nov 15, 2:49 PM UTC
Aberdeen Group plc cut its holdings in Merck and Co., Inc. (NYSE: MRK) by 87.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54... - He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment 247 Wallst, Nov 14, 8:02 PM UTC
A retiree on Original Medicare finishes melanoma surgery and hears about a personalized vaccine that could cut his odds of relapse. Whether he can get it, and who pays for what, hinges on a little-known coverage rule. - 3 Pharmaceutical Stocks That Offer Safety and Growth MarketBeat, Nov 12, 5:12 PM UTC
Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven ... - What Merck KGaA (MRK) Said on Its Q3 Earnings Call MarketBeat, Nov 12, 4:16 PM UTC
Merck KGaA ETR: MRK raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare portfolio. - Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year 247 Wallst, Nov 11, 9:03 PM UTC
A deposit lands every month, but the amounts swing by nearly four times from the smallest check to the largest. Before you build a retirement budget around this fund, see what drives the swings and who should skip it. - Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year 247 Wallst, Nov 11, 7:51 PM UTC
Every one of these drugmakers is staring down a patent cliff, and that looming drop in sales is exactly why their dividends pay what they do. Which one carries the most risk, and which one rewards you most for taking it? - EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Benzinga, Nov 11, 2:56 PM UTC
The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposur... - Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis GuruFocus, Nov 9, 7:00 PM UTC
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinic - INVA or MRK: Which Is the Better Value Stock Right Now? Zacks Investment Research, Nov 9, 5:41 PM UTC
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now? - MRK's 2027 Outlook Challenging, Long-Term Prospects Promising Zacks Investment Research, Nov 9, 2:51 PM UTC
Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential. - Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap 247 Wallst, Nov 8, 11:08 AM UTC
Two men start the same one-minute cancer shot on the same day, yet their Medicare bills will diverge sharply. A hidden enrollment deadline, likely missed years ago, may decide who pays and who doesn't. - Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold? Zacks Investment Research, Nov 6, 7:11 PM UTC
MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth. - MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last? Zacks Investment Research, Nov 5, 2:50 PM UTC
Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth. - November Dogs Of The Dow: No Buys, Yet 5 Are Worth Watching Seeking Alpha, Nov 4, 6:45 PM UTC
Dow Dogs remain pricey with thin dividends, but 21 of 30 are ‘safer' due to robust free cash flow supporting payouts. Analyst targets project 16.96% to 60.26% net gains for top-ten Dow Dogs by November 2027, though ri... - Merck gets US FDA emergency use nod for treatment of screwworm in dogs Reuters, Nov 3, 9:13 PM UTC
Merck gets US FDA emergency use nod for treatment of screwworm in dogs - 3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively Fool - Investing News, Nov 3, 7:31 PM UTC
In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%. - Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial 24/7 Wall Street, Nov 3, 6:53 PM UTC
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231. - Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue. 24/7 Wall Street, Nov 3, 6:03 PM UTC
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything. - Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: AON, Bloom Energy, Chevron, Cloudflare, Marvell Technologies, Lumentum Holdings, Merck & Co., Roku, X-Energy, and More 247 Wallst, Nov 3, 12:59 PM UTC
Tech stocks keep beating estimates and then selling off anyway, Apple just joined the club, and Wall Street analysts are busy reshuffling their ratings on everything from nuclear energy plays to insurance giants. Here... - Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs Fool - Investing News, Nov 2, 2:00 PM UTC
The market for GLP-1 drugs is forecast to explode. It may be understated still. - Moderna, Merck eye FDA approval for promising cancer vaccine Fox Business, Nov 1, 7:00 PM UTC
Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.' #fox #foxbusiness #media #breakingnews #...
Press releases
- Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director Business Wire, Nov 18, 11:45 AM UTC
RAHWAY, N.J.--(BUSINESS WIRE)--Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director. - Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib Business Wire, Nov 17, 9:15 PM UTC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (M... - Merck Announces First-Quarter 2027 Dividend Business Wire, Nov 17, 3:01 PM UTC
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2027 Dividend. - Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season Business Wire, Nov 13, 11:40 AM UTC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medi... - Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy Business Wire, Nov 13, 11:35 AM UTC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHM... - Merck to Participate in the Jefferies Global Healthcare Conference in London Business Wire, Nov 12, 11:45 AM UTC
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference in London. - FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor Business Wire, Nov 10, 6:14 PM UTC
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony sti... - Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis Business Wire, Nov 9, 6:05 PM UTC
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinical trial that evaluated th... - Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations Business Wire, Nov 3, 11:45 AM UTC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial ev... - Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026 Business Wire, Nov 2, 11:45 AM UTC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN. - Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Business Wire, Oct 30, 1:00 PM UTC
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is... - Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline Business Wire, Oct 29, 10:30 AM UTC
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline.
Headlines link to their publishers. Research data, not investment advice.